RxDoctor Payments Data

Andrew Ayers, MD

Cardiovascular Disease · Las Vegas, NVNPI 1326359829

Payments from drug & device makers

$5,489in general payments, 2019–2025

Across 250 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$1K
  • Philips North America LLC$573
  • Amgen$531
  • Novartis$440
  • Merck$426
  • Johnson & Johnson$410
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$5,09193%
  • Education$3987%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,489 in reported general payments places this provider in the 60th percentile of 165 cardiovascular disease providers in Nevada.

See all cardiovascular disease providers in Nevada

Medicare billing

Part B allowed, 2024
$315,385
Medicare patients
468
Services billed
2,990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban174$189,881
EntrestoSacubitril/Valsartan74$109,356
Repatha SureclickEvolocumab96$79,736
XareltoRivaroxaban40$59,206
BrilintaTicagrelor17$11,549
Atorvastatin Calcium574$4,841
Diltiazem 24hr Er (La)Diltiazem Hcl45$4,074
Amlodipine Besylate400$2,129
Losartan Potassium286$2,082
Ezetimibe55$1,976
Metoprolol Succinate136$1,769
Flecainide Acetate58$1,639
Diltiazem 24hr Er (Xr)Diltiazem Hcl55$1,390
Propranolol Hcl59$1,371
Rosuvastatin Calcium105$1,158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$65$189,881174 claims
NovartisEntresto$440$109,35674 claims
Johnson & JohnsonXarelto$410$59,20640 claims
AstraZenecaBrilinta$395$11,54917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 165 cardiovascular disease providers in Nevada.

Other cardiovascular disease in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →